EXECUTIVE ENGAGEMENTS
POOL
892
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
178
Interactions with Platform & by Email
PARTICIPANTS
36
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
36
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
60
PAGES
126
EDITION
7
PRICE
USD 5600
CODE
MCP21058
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Advanced Therapy Medicinal Products estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$10.8 Billion by 2027, growing at a CAGR of 17% over the analysis period 2020-2027. Cell Therapy, one of the segments analyzed in the report, is projected to record a 16.6% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Tissue Engineered Product segment is readjusted to a revised 17.4% CAGR for the next 7-year period.
The Advanced Therapy Medicinal Products market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 16.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.1% and 14.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.
In the global Gene Therapy segment, USA, Canada, Japan, China and Europe will drive the 18.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$556.8 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.
SELECT PLAYERS
Bluebird Bio, Inc.; Celgene Corporation; Gilead Lifesciences, Inc.; JCR Pharmaceuticals Co., Ltd.; Kolon TissueGene, Inc.; MEDIPOST; Novartis AG; Organogenesis, Inc.; PHARMICELL Co., Ltd; Spark Therapeutics, Inc.; UniQure N.V.; Vericel Corporation
SEGMENTS
» Type (Cell Therapy, Tissue Engineered Product, Gene Therapy, CAR-T Therapy)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Advanced Therapy Medicinal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Tissue Engineered Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Tissue Engineered Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Tissue Engineered Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for CAR-T Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for CAR-T Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for CAR-T Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Advanced Therapy Medicinal Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Advanced Therapy Medicinal Products by Type - Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineered Product, Gene Therapy and CAR-T Therapy for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 36 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com